Table 1.
Characteristics of patients receiving allogeneic transplantation for neuroblastoma between 1990-2007 and registered to the CIBMTR
| Characteristics of patients | Did not receive prior auto, N (%) |
Received prior auto, N (%) |
|---|---|---|
| Number of patients | 97 | 46 |
| Number of centers | 48 | 24 |
| Age at transplant, median (range), years | 5 (<1- 55) | 7 (2-32) |
| 0 – 5 | 51 (53) | 9 (20) |
| 6 -10 | 27 (28) | 31 (67) |
| 11 – 20 | 13 (13) | 5 (11) |
| > 20 | 6 ( 6) | 1 ( 2) |
| Male sex | 58 (60) | 23 (50) |
| Karnofsky score prior to TX | ||
| < 90% | 13 (13) | 11 (24) |
| ≥ 90% | 39 (40) | 28 (61) |
| Unknown | 45 (46) | 7 (15) |
| Time from diagnosis to allogeneic transplant | ||
| Median (range), months | 9 (<1-97) | 27 (8 - 76) |
| ≤ 6 | 12 (12) | 0 |
| 7 12 | 50 (52) | 3 ( 7) |
| 13 – 24 | 19 (20) | 10 (22) |
| 25 – 36 | 6 ( 6) | 18 (39) |
| > 36 | 9 ( 9) | 15 (33) |
| Missing | 1 ( 1) | 0 |
| Had prior autologous transplant | 46 (100) | |
| Time from autologous transplant to allogeneic transplant | ||
| Median (range), months | NA | 20 (1- 68) |
| 0 - 12 | 10 (22) | |
| 13 – 24 | 19 (41) | |
| 24 – 36 | 17 (37) | |
| Disease status prior to transplant | ||
| CR | 30 (31) | 8 (17) |
| Very good partial response | 8 ( 8) | 4 ( 9) |
| Partial response | 17 (18) | 8 (17) |
| Minimal response | 1 ( 1) | 1 ( 2) |
| No response | 17 (18) | 2 ( 4) |
| Progressive disease | 6 ( 6) | 11 (24) |
| Unknown | 18 (19) | 12 (26) |
| Conditioning regimen | ||
| TBI + other | 59 (61) | 15 (33) |
| Bu + CY ± Other | 4 ( 4) | 1 (2) |
| CY + other | 6 ( 6) | 7 (15) |
| Bu + Fludara ± Other | 3 ( 3) | 6 (13) |
| Bu + Other | 1 ( 1) | 3 ( 7) |
| Melphalan + Fludara ± other | 3 ( 3) | 9 (20) |
| Melphalan ± Other | 11 (11) | 0 |
| Othera | 2 ( 2) | 0 |
| Unknown | 8 ( 8) | 5 (11) |
| Donor type | ||
| HLA-identical sibling | 56 (58) | 18 (39) |
| Other related donor | 25 (26) | 4 (9) |
| Unrelated | 16 (16) | 24 (52) |
| Graft source | ||
| BM | 69 (71) | 16 (35) |
| PBSC | 10 (10) | 13 (28) |
| Cord Blood | 16 (16) | 17 (37) |
| Unknown | 2 (2) | 0 |
| Year of transplant | ||
| 1990 – 1994 | 38 (39) | 1 ( 2) |
| 1995 – 1999 | 26 (27) | 10 (22) |
| 2000 – 2004 | 24 (25) | 18 (39) |
| 2005 – 2007 | 9 ( 9) | 17 (37) |
| GVHD prophylaxis | ||
| T-cell depletion | 5 ( 5) | 1 ( 2) |
| MTX + CSA ± other | 21 (22) | 9 (20) |
| MTX ± other | 19 (20) | 3 (7) |
| CSA ± Other | 30 (31) | 23 (50) |
| Other | 1 ( 1) | 3 ( 7) |
| Unknownb | 21 (22) | 7 (15) |
| Median (range) follow-up c, months | 84 (<1- 191) | 45 (<1- 58) |
Abbreviations: TBI = total body irradiation; CY = cyclophosphamide; CsA = cyclosporine; MTX = methotrexate; CMV = cytomegalovirus; GVHD = graft-versus-host disease; FK506 = tacrolimus.